478 related articles for article (PubMed ID: 17505263)
1. Recombinant interferon alpha-2b and coenzyme Q10 as a postsurgical adjuvant therapy for melanoma: a 3-year trial with recombinant interferon-alpha and 5-year follow-up.
Rusciani L; Proietti I; Paradisi A; Rusciani A; Guerriero G; Mammone A; De Gaetano A; Lippa S
Melanoma Res; 2007 Jun; 17(3):177-83. PubMed ID: 17505263
[TBL] [Abstract][Full Text] [Related]
2. Postsurgical adjuvant therapy for melanoma. Evaluation of a 3-year randomized trial with recombinant interferon-alpha after 3 and 5 years of follow-up.
Rusciani L; Petraglia S; Alotto M; Calvieri S; Vezzoni G
Cancer; 1997 Jun; 79(12):2354-60. PubMed ID: 9191523
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
Eggermont AM; Suciu S; Testori A; Santinami M; Kruit WH; Marsden J; Punt CJ; Salès F; Dummer R; Robert C; Schadendorf D; Patel PM; de Schaetzen G; Spatz A; Keilholz U
J Clin Oncol; 2012 Nov; 30(31):3810-8. PubMed ID: 23008300
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant therapy for resected stage III melanoma patients: high-dose interferon-alpha versus ipilimumab combined with kinases inhibitors.
Minutilli E; Feliciani C
Tumori; 2012; 98(2):185-90. PubMed ID: 22677983
[TBL] [Abstract][Full Text] [Related]
5. Duration of high-dose interferon alpha-2b regimen for resected high-risk melanoma.
Agarwala SS; Gray RJ; Wong MK
J Clin Oncol; 2009 Sep; 27(25):e82-3; author reply e84. PubMed ID: 19635995
[No Abstract] [Full Text] [Related]
6. Serum concentrations of pegylated interferon alpha-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon alpha-2b in a randomized phase III trial (EORTC 18991).
Eggermont AM; Bouwhuis MG; Kruit WH; Testori A; ten Hagen T; Yver A; Xu C
Cancer Chemother Pharmacol; 2010 Mar; 65(4):671-7. PubMed ID: 19621225
[TBL] [Abstract][Full Text] [Related]
7. Perioperative adjuvant biotherapy in high-risk resected cutaneous melanoma: the results of 5 years of follow-up.
Elias EG; Zapas JL; Beam SL; Culpepper WJ
Melanoma Res; 2007 Oct; 17(5):310-5. PubMed ID: 17885586
[TBL] [Abstract][Full Text] [Related]
8. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
[TBL] [Abstract][Full Text] [Related]
10. Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha.
Satzger I; Meier A; Schenck F; Kapp A; Hauschild A; Gutzmer R
Int J Cancer; 2007 Dec; 121(11):2562-6. PubMed ID: 17680564
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.
Richtig E; Hofmann-Wellenhof R; Pehamberger H; Forstinger Ch; Wolff K; Mischer P; Raml J; Fritsch P; Zelger B; Ratzinger G; Koller J; Lang A; Konrad K; Kindermann-Glebowski E; Seeber A; Steiner A; Fialla R; Pachinger W; Kos C; Klein G; Kehrer H; Kerl H; Ulmer H; Smolle J
Br J Dermatol; 2004 Jul; 151(1):91-8. PubMed ID: 15270876
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
[TBL] [Abstract][Full Text] [Related]
13. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous melanoma: interferon alpha adjuvant therapy for patients at high risk for recurrent disease.
Lens M
Dermatol Ther; 2006; 19(1):9-18. PubMed ID: 16405565
[TBL] [Abstract][Full Text] [Related]
15. Intermittent High-Dose Intravenous Interferon Alfa-2b for Adjuvant Treatment of Stage III Melanoma: Final Analysis of a Randomized Phase III Dermatologic Cooperative Oncology Group Trial.
Mohr P; Hauschild A; Trefzer U; Enk A; Tilgen W; Loquai C; Gogas H; Haalck T; Koller J; Dummer R; Gutzmer R; Brockmeyer N; Hölzle E; Sunderkötter C; Mauch C; Stein A; Schneider LA; Podda M; Göppner D; Schadendorf D; Weichenthal M
J Clin Oncol; 2015 Dec; 33(34):4077-84. PubMed ID: 26503196
[TBL] [Abstract][Full Text] [Related]
16. [Long-term results of adjuvant chemotherapy after therapeutic lymph node dissection in patients with cutaneous malignant melanoma].
Kretschmer L; Helmbold P; Emmert S; Marsch WC
Hautarzt; 2002 Aug; 53(8):536-41. PubMed ID: 12221468
[TBL] [Abstract][Full Text] [Related]
17. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.
Keilholz U; Punt CJ; Gore M; Kruit W; Patel P; Lienard D; Thomas J; Proebstle TM; Schmittel A; Schadendorf D; Velu T; Negrier S; Kleeberg U; Lehman F; Suciu S; Eggermont AM
J Clin Oncol; 2005 Sep; 23(27):6747-55. PubMed ID: 16170182
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial.
Hauschild A; Weichenthal M; Rass K; Linse R; Berking C; Böttjer J; Vogt T; Spieth K; Eigentler T; Brockmeyer NH; Stein A; Näher H; Schadendorf D; Mohr P; Kaatz M; Tronnier M; Hein R; Schuler G; Egberts F; Garbe C
J Clin Oncol; 2010 Feb; 28(5):841-6. PubMed ID: 20048184
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
Hwu WJ; Panageas KS; Menell JH; Lamb LA; Aird S; Krown SE; Williams LJ; Chapman PB; Livingston PO; Wolchok JD; Houghton AN
Cancer; 2006 Jun; 106(11):2445-51. PubMed ID: 16639739
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR
J Clin Oncol; 2003 Jul; 21(13):2551-7. PubMed ID: 12829675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
